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Objective: The purpose of this study was to evaluate the short-term and long-term results of simultaneous surgical
treatment of coexisting abdominal aortic aneurysm and bladder carcinoma.
Methods: A prospective study was carried out to compare patients undergoing simultaneous surgical treatment of
abdominal aneurysm and bladder carcinoma with control patients undergoing surgery for either one of the two diseases
alone. From January 1995 to December 2000, 16 consecutive patients were seen with concomitant abdominal aortic
aneurysm and bladder carcinoma at our institutional referral center. All patients underwent a standard operative protocol
that included aneurysm graft replacement, radical cystoprostatectomy, and urinary reconstruction. Endovascular
treatment of the aneurysm was considered in the last 2 years of the study. After each simultaneous treatment case, two
control patients were selected according to the same type of vascular or urinary procedure, respectively, and pathologic
staging. The analyzed endpoint was mortality, and confounder variables included common and disease-specific risk
factors. Frequencies of vascular, urologic, and systemic complications were carefully considered with special attention to
graft infection and tumor recurrence.
Results: Endovascular treatment was not performed for morphologic reasons. No perioperative mortality was observed.
A trend toward inferior survival rates in simultaneously treated patients was observed in the early follow-up period, but
survival analysis with log-rank test showed no statistical difference among the groups (P .19). Cox proportional hazard
model results proved no influence of the different group treatments on survival (P .49) and no influence of age and risk
factors, except for preoperative renal status (P .015). The increased mortality rate of the simultaneous treatment group
could be ascribed to the presence of preoperative moderate renal insufficiency in two study group patients. Long-term
survival of treated patients is mainly dependent on cancer progression. Graft infection and other vascular complications
were not observed. Systemic and urologic complications were similar in study and control groups.
Conclusion: This study shows that the simultaneous surgical approach to coexisting abdominal aortic aneurysm and
transitional cell carcinoma of the bladder represents a suitable choice of treatment in highly specialized centers, but
patients with preoperative renal insufficiency should be carefully evaluated. Endovascular treatment represents an
appealing alternative whenever indicated. (J Vasc Surg 2003;37:607-14.)
The frequency of both abdominal aortic aneurysm
(AAA) and visceral malignant disease increases with advanc-
ing age. At the time of AAA reconstruction, the chance to
encounter intra-abdominal malignant disease has been
found in up to 4% of patients.1 Surgical treatment of the
two potentially life-threatening conditions still represents
the best option in many instances, but the best timing of
intervention is controversial. The main concern is that
aneurysm repair performed simultaneously with other ma-
jor nonvascular procedures, involving potentially infected
body fluids, would increases the risk of graft infection. The
staged procedure is not without risk either, necessitating a
second anesthesia, major surgery in a complex cicatricial
territory, and the delay of definitive therapy of one of two
potentially life-threatening diseases. Technical complica-
tions are particularly challenging in the staged management
of AAA and invasive carcinoma of the bladder. A major
urologic resection and possible bladder reconstruction or
AAA resection is undertaken in an abdomen obliterated by
the first-stage treatment of either disease. Transperitoneal
AAA repair after bladder resection and ileal-bladder recon-
struction proved to be extremely complex in four patients
of our earlier experience. Retroperitoneal approach to AAA
repair after surgical transitional cell carcinoma of the blad-
der (TCCB) treatment could have the advantage of being
better tolerated by the patients, with avoidance of the risks
of intraperitoneal adhesions. However, because of the ret-
roperitoneal fibrosis and possible adhesions between the
aneurysm wall and the ileal-bladder reconstruction, access
to distal common iliac vessels could prove equally treach-
erous in the retroperitoneal approach. Therefore, the
staged approach was not considered a fair choice for pa-
tients with coexisting diseases, and a standard collaborative
protocol was devised to simultaneously treat all patients
with AAA and TCCB. A prospective study was undertaken
to examine whether the results of the combined approach
were not significantly worse than treatment of either disease
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alone. Mortality and morbidity rates of simultaneously
treated patients were compared with control matched pa-
tients undergoing surgery for either AAA or TCCB as
individual procedures.
MATERIALS AND METHODS
From January 1995 to December 2000, 527 patients
underwent AAA graft replacement and 530 patients under-
went radical cystoprostatectomy for a TCCB. Sixteen con-
secutive patients (3%) had concomitant AAA and TCCB
and underwent simultaneous surgical treatment.
Indications for surgery included aneurysm size exceed-
ing 4.5 cm, whenever the diameter ratio between AAA and
proximal native aorta was greater than 2, and clinical TCCB
stage of T2 or more without metastases. Beginning in
January 1999, patients with concomitant AAA and TCCB
were evaluated for the endovascular treatment of AAA.
Clinical TCCB stage of less than T2 was considered for
bladder resection if the disease was nonresponsive to re-
peated cycles of local immunotherapy and chemotherapy.
All patients were initially evaluated for urinary symp-
toms, including hematuria, dysuria, and pain on urination.
Patients underwent a thorough physical examination, a
complete panel of blood tests, abdominal computed tomo-
graphic (CT) scanning, cystoscopy with cancer resection/
biopsy, digital subtraction angiography, and more recently,
three-dimensional spiral abdominal CT angiography. Bone
scan was routinely performed for tumor staging. Before
surgery, all patients underwent electrocardiography, chest
radiography, and carotid duplex scanning. When indicated,
noninvasive cardiac stress testing, either dobutamine echo-
cardiography or the dipyridamol thallium stress test, and
pulmonary function tests were performed. Risk factors and
associated diseases considered were diabetes, tobacco use,
hypertension, hyperlipemia, cardiac status, carotid disease,
renal status, and pulmonary status, defined and graded
according to the Society for Vascular Surgery/Interna-
tional Society for Cardiovascular Surgery recommended
criteria.2
The day before surgery, patients were admitted to the
hospital and received mechanical thorough bowel prepara-
tion. All patients were given broad-spectrum antibiotics
before surgery.
Operative technique. A standard operative protocol
was established in patients with simultaneously occurring
invasive TCCB and AAA. AAA was always addressed first. A
xipho-pubic incision and transperitoneal approach was per-
formed. Attention was given to retain enough tissue from
the aneurysm wall to cover anastomoses and prosthetic
graft completely, whenever possible. The retroperitoneum
was closed accurately with a double layer of nonabsorbable
nylon monofilament material. When the retroperitoneum
was inadequate to guarantee a tight seal of the vascular
reconstruction, the transmesocolic great epiploon was used
as the second layer of sealing.
Access to the bladder was obtained with standard pre-
peritoneal and retroperitoneal incisions, away from vascular
access lines. Radical cystoprostatectomy was carried out,
followed by pelvic lymphadenectomy to the proximal ex-
ternal and internal iliac arteries. Preaortic and common iliac
artery lymphadenectomy was performed only when nodes
were macroscopically involved, at the time of vascular re-
construction. In the case of external iliac revascularization,
lymphadenectomy in the proximal iliac vessels was also
accomplished at the time of vascular reconstruction. Pa-
tients underwent either an orthotopic ileal bladder recon-
struction (OIBR) according to the vescica ileale padovana
(padua ileal neobladder) technique previously described by
Pagano et al3 or an ileal loop urinary diversion (ILUD)
according to the Bricker4 or Wallace5 technique. The deci-
sion on the type of urologic reconstructions was based on
the informed patient consensus, the urology team judg-
ment of the patient’s ability to manage the neobladder
reservoir, and on preoperative and macroscopically tumor
staging of less than T4. The ileum was carefully surrounded
and isolated from the retroperitoneum with surgical wraps.
At the end of the reconstruction, prolonged pelvic cavity
lavages with antiseptic and antibiotic solutions were re-
peated and indwelling catheters were placed into the ure-
ters going out of the abdominal wall and into the neoblad-
der through the urethra. A pelvic cavity drainage was
positioned through the abdominal wall, and the retroperi-
toneum was sealed. After surgery, patients were transferred
to the intensive care unit.
Postoperative course and follow-up. Patients re-
ceived a prolonged postoperative antibiotic therapy until all
the indwelling catheters were removed. The ureteral cath-
eters were consecutively removed on postoperative days 8
and 9. Radiographic control of the OIBR was performed
through the urethra catheter to exclude any urinary leak at
postoperative day 10. If any leak was present, the catheter
would be left in situ and a new radiographic control sched-
uled after 10 days. Special attention was directed to detect
any sign of infection in the postoperative period.
Patients with a continent OIRB were instructed and
trained by physical therapists to void their neobladder
reservoir. Pathologic tumor staging was determined ac-
cording to the tumor nodes metastasis system proposed by
the International Union Against Cancer.6
All patients underwent clinical, laboratory, and ultra-
sound scan examinations at 1, 4, 8, and 12 months after
surgery and every 6 months thereafter. Abdominal CT and
bone scans were obtained at 6 and 12 months after surgery
and yearly thereafter (Fig 1). Labeled leukocytes scan
(LLS) was performed at 12 months after surgery to detect
any silent graft infection.
Study design. For comparison of the results of the
simultaneous AAA and TCCB treatment (group A), a
prospective study was carried out, with two equal-sized
(n  16) groups of matched control patients undergoing
surgery for either AAA (group B) or TCCB (group C)
alone. After each simultaneous treatment case, two control
patients were selected according to the time of surgery
(within 6 months of a simultaneous case), gender, vascular
(tube or bifurcated graft), or urologic (VIP or ILUD)
reconstruction, respectively, and pathology tumor staging.
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Only compliant patients entered the study after informed
consensus. Control patients were followed up with the
same schedule, except for CT scan and bone scan in group
B patients and LLS in group C patients.
The analyzed endpoint was mortality, and confounder
variables included common and disease-specific risk factors.
Frequency of vascular, urologic, and systemic complica-
tions were carefully considered, with special attention to
graft infection and tumor recurrence. All data were col-
lected on a spreadsheet database (Excel, Microsoft, Inc,
Seattle, Wash), and statistical analysis was performed with
the SPSS v10.1 software (SPSS, Inc, Chicago, Ill).
Fisher exact test was used to compare prevalence of
graded risk factors among the patient groups. Kaplan-
Meier method with log-rank tests was used to estimate and
compare survival among the different groups. A two-sided
P value of .05 was considered the limit of statistical signif-
icance. Cox proportional hazard model was applied to
estimate the influence of risk factors (covariates) and
groups (forced covariate) on survival. Covariates entered
the model with the stepwise forward method (P to enter
.05; P to remove  .10).
RESULTS
Patients characteristics and surgical treatment. All
patients were male. The ages ranged from 61 to 79 years
(mean  standard deviation [SD], 70  5 years) in group
A, from 56 to 82 years (mean SD, 71 7 years) in group
B, and from 47 to 79 years (mean  SD, 64  9 years) in
group C. Table I shows moderate and severe (Society for
Vascular Surgery/International Society for Cardiovascular
Surgery classification) risk factors in the three groups of
patients. For comparison of prevalence of risk factors (in-
cluding all four grades) among the three patient groups,
4 3 contingency tables were generated and analyzed with
Fisher exact test. No statistical difference was observed,
although the prevalence of moderate renal insufficiency was
relevant in group A (P  .08).
Aneurysm size in group A ranged from 4.5 to 8 cm and
was greater than 5.5 cm in 10 patients (mean  SD, 5.5 
1 cm). All patients had an infrarenal aneurysm and had
open surgical repair. Aortic reconstruction consisted of 10
tube and six aortobiiliac grafts. The sites of distal anasto-
moses were the common iliac arteries bilaterally in four
patients, the right common and left external iliac arteries
with exclusion of a left internal iliac aneurysm in one
patient, and the right internal and the left external arteries
with a graft to right external iliac bypass and exclusion of a
left internal iliac aneurysm in one patient. None of the study
group patients had an indication to endovascular treatment
of AAA in the last 2 years of the study. Reasons for endo-
vascular AAA treatment exclusion included the presence of
a short (10 mm) proximal neck in two patients, an acute
proximal aortic angle of less than 120 degrees in one
patient, a bilateral common iliac artery aneurysm extending
to the bifurcation in two patients, a tortuous iliac artery
(iliac tortuosity index , 1.6) with more than 50% calcifi-
cation of the segment length in one patient, and the pres-
ence of an accessory renal artery departing from the aneu-
rysm in one patient. One patient underwent a concomitant
aortorenal bypass for a greater than 90% right renal artery
stenosis, and the previously mentioned patient, reimplan-
tation of the accessory renal artery into the aortic graft. In
group B, aortic reconstruction consisted of 10 tube and six
bifurcated grafts, all to the common iliac arteries.
In group A, urinary reconstruction included OIBR-
VIP in 11 patients and ILUD in five. The urinary diversion
Fig 1. Abdominal CT scan 12 months after simultaneous surgical
treatment of coexisting AAA and TCCB. Figure shows multislice
spiral CT scan tridimensional reconstruction of OIBR according to
VIP technique and bifurcated aortic graft replacement.
Table I. Risk factors and overall mortality
Grade  2* Group A Group B Group C P†
Diabetes 0 0 0 .91
Tobacco use 6 (37%) 4 (25%) 9 (56%) .12
Hypertension 5 (31%) 5 (31%) 4 (25%) .74
Hyperlipemia 0 0 0 .66
Cardiac status 8 (50%) 9 (56%) 10 (62%) .65
Carotid disease 0 0 2 (13%) .23
Renal status 2 (13%) 0 0 .08
Pulmonary status 5 (31%) 2 (13%) 3 (19%) .89
*Risk factors were defined and graded according to Society for Vascular
Surgery/International Society for Cardiovascular Surgery recommended
criteria.2
†P values according to Fisher exact test analysis on 3 4 contingency tables
generated from three treatment groups (A, B, and C) versus four grades (0
to 3) of each risk factor.
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was accomplished according to the Wallace5 (n  2) or
Bricker4 (n  3) technique because patients were consid-
ered unable to manage the learning process for voiding the
urinary reservoir (n 4) and for staging T4 at surgery (n
1). According to the research protocol, group C patients
underwent the same type of urinary reconstruction, and
indications to ILUD were identical. All patients had a
histopathologically proven transitional cell carcinoma. Tu-
mor staging is shown in Table II. Nodal involvement (N1)
was present only in the T4 patients. No metastases were
observed. A concomitant localized prostate carcinoma
(T2) was histopathologically proven in five patients of
both groups A and C. The prostatectomy was considered
curative, and patients did not receive any adjuvant therapy
for prostate cancer.
The group A average estimated blood loss was higher
(1650 550 mL) than in both groups B (850 300 mL)
and C (1150  600 mL) but below the total amount of
groups B and C collectively considered. The time required
to complete the urinary procedure alone (6  1.5 hours)
was not considerably increased by the concomitant aneu-
rysm repair (7.4 1.75 hours), with the vascular procedure
alone being much faster (2.5  0.75 hours) and with
laparotomy and abdominal wall closure common steps to
both procedures.
Hospital course. The mean hospital stay was the same
in groups A and C and was dependent on TCCB treatment
(data not shown). Postoperative complications are shown
in Table III. No postoperative mortality was observed. The
incidence rates of postoperative systemic complications
were 25% in group A, 6.2% in group B, and 25% in group C.
Deep vein thrombosis with pulmonary embolism was the
most common systemic complication (two patients in
group C and one in group A), followed by ventricular
arrhythmias (one patient each in groups A and C) and
requiring cardioversion in one case.
No graft infection or other vascular complications were
seen, whereas the incidence rate of urologic complications
was 19% in group A and 25% in group C. Two group A
patients with orthotopic bladder reconstructions had a
monolateral ureteral obstruction, whereas one group C
patient had a bilateral ureteral obstruction, requiring tem-
porary nephrostomy and double J stent placement. One
patient in group A had an extensive fluid collection develop
in the pelvic cavity in the proximity of the left graft limb
anastomosis, with no direct continuity with the prosthesis
(Fig 2). Needle aspiration was performed with CT scan
guidance. The fluid proved to be an uncontaminated lym-
phatic leak on chemical and microbiologic examination.
The fluid collection disappeared after 1 month, and no
evidence of graft infection was seen on LLS 1 year after
surgery.
Two patients in both groups A and C showed a leak of
contrast dye at the radiographic control of the neobladder
10 days after surgery. The catheter was left in situ and
removed on an outpatient basis 10 or 20 days later, when
the following radiographic control showed no dye leakage.
Follow-up. Patients showed no evidence of active or
silent graft infection on laboratory or CT and LLS scan
examinations. The group A mean follow-up length was 28
months (SD,  24 months); 10 patients are still alive
without evidence of disease, and six patients died, four of
metastatic disease at 6 months (n  2), at 16 months (n 
1), and at 29 months (n  1) from surgery and one of
myocardial infarction and one of congestive cardiac failure
at 2 and 5 months, respectively, after worsening of a pre-
operative moderate renal insufficiency.
The group B mean follow-up length was 42 months
(SD,  26 months). Fourteen patients are still alive, and
two died, one of lung carcinoma (at 8 months) and one of
congestive cardiac failure (at 21 months).
The group C mean follow-up length was 35 months
(SD, 24 months). Twelve patients are still alive, and four
died, three of metastatic disease at 6, 14, and 20 months
after surgery and one as a consequence of intestinal occlu-
sion and peritonitis 66 months after surgery.
Table II. Tumor characteristics and outcome in patients
with TCCB
Group A Group C
Tumor stage
Is nonresponder 1 2
1 nonresponder 2 1
2 6 6
3a 3 2
3b 1 2
4a (N1) 1 1
Tumor grade
I 2 2
II 6 8
III 8 6
Recurrent TCCB 4 4
Outcome
Alive 10 12
Dead metastatic 4 3
Dead NED 2 1
NED, No evidence of disease (TCCB).
Table III. Postoperative complications
Group A Group B Group C
Systemic 25% 6% 25%
MI 1
DVT & PE 1 2
CHF 1
GI bleeding 1*
Ventricular arrhytmias 1 1
Pneumonia 1
Vascular 0 0
Urologic 19% 25%
Ureteral obstruction 2 2A†
Lymphocele 1
Pyelonephritis 1
Retroperitoneal hematoma 1‡
*Same patient with DVT & PE.
†One patient with bilateral obstruction.
‡Same patient with pyelonephritis.
MI, Myocardial infarction; DVT & PE, deep vein thrombosis and pulmo-
nary embolism; CHF,congestive heart failure; GI, gastrointestinal bleeding.
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Fig 3 shows Kaplan-Meier survival estimate curves of
the three groups. A trend toward increased early mortality
in group A was observed. Considering the small sample size
and the increased early mortality in group A, the standard
error of survival estimate exceeded 10% after 6 months,
whereas it exceeded this limit at 34 and 20 months in
groups B and C, respectively. Taking into account this
limitation, the log-rank test analysis showed no statistical
difference of survival among groups (P  .19). Cox pro-
portional hazard model proved no influence of the different
groups on survival (P  .49) and no influence of age and
risk factors, except for preoperative renal status (P .015).
The presence of preoperative moderate renal insufficiency
in two group A patients (Table I) could explain the de-
creased survival rate of the simultaneous treatment group in
the early follow-up period. The long-term decreased sur-
vival rate associated with groups A and C compared with
group B is to be ascribed to cancer progression.
One control group C patient underwent nephrouter-
ectomy for a new focus of TCC in the left ureter after 21
months. The patient is still alive after 56 months of cys-
toprostatectomy and free of recurrence. Anatomic and
functional complications were observed in patients with a
neobladder reservoir. Ureter-neobladder stenosis was ob-
served in two patients of group A and in three of group C
after a period ranging from 4 to 20 months. Patients
underwent nephrostomy and temporary double J stent
positioning, and two group C patients needed a subsequent
terminal ureterectomy and neobladder reimplantation.
Two patients of group A were unable to manage the
physical maneuvers to void to neobladder. One of them
needed the conversion of the VIP reconstruction into
ILUD, the other managed to void the neobladder with
periodical self-catheterization. One patient in both groups
A and C had nocturnal incontinence.
DISCUSSION
The reported incidence rate of concomitant AAAs and
abdominal malignant disease is not consistent on published
papers, depending on the incidence rate of AAA and ma-
lignant diseases considered. Morris and Colquitt7 found an
incidence rate of 12.7% in review of the record of 158
patients with AAA (including nonoperative management)
and all histologically proven malignant diseases. With con-
sideration of only the AAA undergoing treatment, Szilagyi,
Elliot, and Berguer1 observed a combined incidence rate of
Fig 2. Extensive pelvic fluid collection (dotted arrow line) in proximity of left graft limb anastomosis (solid arrow line)
was observed in one group A patient at 1 month after surgery (A). Fluid showed no direct continuity with prosthesis.
Needle aspiration was performed with CT scan guidance, and fluid collection disappeared after 2 months of CT scan
control (B). No evidence was seen of graft infection at technetium99 LLS 1 year after surgery (C).
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3.9% with all malignant diseases, whereas the combination
with a colorectal malignant disease ranged from 0.5% to
1.4% in different reports.1,8,9 No published data are avail-
able on the incidence rate of concomitant AAA and carci-
noma of the bladder. In this study, an incidence rate of 3%
was observed over a 6-year period. This incidence rate
appears to be rather high, considering on the one hand
published reports on the incidence rate of AAA and other
malignant diseases and on the other that both diseases were
surgically managed. The increasing use of more sophisti-
cated CT scan and ultrasonographic devices for preopera-
tive cancer evaluation and AAA detection may in part
explain the relatively high incidence rate of the combina-
tion observed. Moreover, Padua University Hospital is a
national referral center for both complex vascular and uro-
logic diseases, and difficult cases are sent to observation
with an increased frequency. Finally, six small aneurysms
(4.5 to 5.5 cm of maximal diameter) were surgically ad-
dressed in this study, considering both the difficulty of
treatment in case of aneurysm enlargement after bladder
resection and urinary reconstruction and the low hospital
postoperative AAA mortality rate in elective cases (3%;
unpublished data). In the series presented by Ginsberg et
al,10 seven patients had a concomitant TCCB and a small
aneurysm (diameter, 3.1 to 5.5 cm) that was left in situ.
Four patients of this group subsequently needed AAA
resection, and at least one other patient died of a ruptured
aneurysm.
The major dilemma is represented by the choice of
treatment in patients with simultaneously occurring AAA
and TCCB. Various therapeutic options are available for
the treatment of invasive carcinoma of the bladder. So far,
radical cystoprostatectomy with urinary diversion remains a
mainstay of treatment for suitable candidates.
Although endovascular treatment is now available for
AAA, the conventional method of AAA repair with open
surgery still remains the most common and the safer option
for treatment. Endovascular AAA graft exclusion may pro-
vide the best protection of the prosthetic material from
bowel and urinary spill during gastrointestinal and urinary
tract manipulation. Unfortunately, not all aneurysm are
anatomically suitable for endovascular repair,11 and despite
the improvements of second-generation devices, the inci-
dence rate of graft failure is still significantly higher in
endovascular compared with open AAA treatment.12 En-
dovascular graft complications include aortic rupture, en-
dograft migration obstructing iliac outflow, persistent en-
doleak after unsuccessful secondary endoluminal repair,
and endograft infection, which all represent indications to
open repair. In the presence of OIBR or ILUD and cicatri-
cial obliteration, elective or emergency open repair may
present formidable technical challenges.
In the last 2 years of this study, when the endovascular
treatment was introduced at our institution, no patient
with concomitant AAA and TCCB was considered suitable
for such treatment (52 of 235 patients underwent endovas-
cular AAA graft exclusion in the same period). One patient,
not included in this series, previously treated with radical
cystoprostatectomy and VIP replacement, had a 5-cm an-
eurysm develop years later and was successfully treated with
endovascular graft exclusion. It should be finally considered
that endovascular repair of AAA considerably increases
costs of simultaneous treatment of both disease, without
reducing postoperative complications, the length of hospital
Fig 3. Kaplan-Meier survival estimate curves in group A (concomitant AAA and TCCB), group B (AAA alone), and
group C (TCCB alone). Symbol () indicates event dead, whereas  shows censored data. Dotted lines represent
survival estimates when standard error exceeds 10%. With consideration of small sample size and increased early
mortality rate in group A, standard error of survival estimate exceeds 10% after 6 months. Taking into account this
limitation, log-rank test analysis showed no statistical difference of survival among groups (P .19). Kaplan-Meier data
are available as Appendices A and B (online only).
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stay, and the time to return to work, mainly dependent on
magnitude of urologic intervention.
When simultaneous open surgery is performed for both
AAA and TCCB, the major concern is possible contamina-
tion from gastrointestinal or urinary tract content and,
therefore, the best timing of intervention. In a series of
eight patients with synchronous aneurysm and invasive
bladder cancer, Lierz et al13 ruled out the simultaneous
treatment for the potential of graft infection. The authors
treated all their patients with a staged approach, favoring
the AAA repair first (four patients) when the aneurysm was
greater than 5 cm in diameter because of the postoperative
high risk of AAA rupture after a laparotomy performed for
a different disease. Swanson et al14 reported this complica-
tion in 10 patients with asymptomatic aneurysms greater
than 6 cm in size within 36 days of laparotomy. One
prospective study15 showed that the probability of rupture
for an AAA after an unrelated operative procedure averaged
3%.
Subsequent aneurysm repair may also risk ureteral or
bowel injury with direct transection or with vascular com-
promise. On the other hand, as Lierz et al13 pointed out,
repair of the aneurysm before cancer resection potentially
allows for further growth and spread of tumor in a patient
weakened and possibly immunocompromised by a major
procedure. Finally, in the authors’ opinion, the risk of graft
infection is not completely eliminated if the graft is incom-
pletely healed with protective fibrous capsule and neoin-
tima.
Ginsberg et al10 criticized the two-staged approach
because of all the previous considerations and also the
difficulties found at the time of the second operation from
the obliterative cicatricial destruction of tissue planes in the
retroperitoneum. They presented a series of 12 patients
undergoing resection of the urologic neoplasm followed by
AAA resection with the same anesthesia. Less technical
problems were encountered, average blood loss was re-
duced, and operative time was shorter compared with the
staged approach. Furthermore, no graft infections or vas-
cular complications occurred in the follow-up period.
In a recent review, Morris and da Silva16 questioned the
relevance of two previous studies because of lack of treat-
ment protocol. Both retrospective studies did not define
the reasons for choosing each of the management options
for any particular patients.
In the prospective study presented, a simplified, well-
defined, and collaborative treatment was established. A
simultaneous approach was proposed to all patients with an
indication to open surgery treatment for concomitant AAA
and TCCB. The simultaneous intervention was performed
by both vascular and urology specialists.
In contrast to the approach proposed by Ginsberg et
al10, AAA was always resected and replaced first. This
approach was favored because the operative field is not
obstructed by the urinary bladder reconstruction, which
lays anterior to the aortic bifurcation, making the AAA
resection and graft anastomoses more difficult and at risk of
contamination. On the contrary, the vascular graft carefully
surrounded and sealed by the aneurysmal wall and retro-
peritonel tissue does not encumber the surgical field during
cystoprostatectomy and bladder reconstruction. The retro-
peritoneum is carefully closed before the urology proce-
dure to avoid working on the same surgical dissection
planes as much as possible. Any vascular intestinal ischemia
can also be verified before the urologic reconstruction.
The choice of control group patients in this study may
be criticized. Comparison with a staged treatment group of
patients would have been more appropriate, and for this
reason, this study may be considered like a review of the
simultaneous approach more than a comparison with a true
alternative treatment. However, the staged approach was
not considered a fair choice for patients with coexisting
diseases for the reasons previously explained, and given the
rarity of the diseases association, the small sample size of the
two groups would have not been adequate for any valuable
comparison. The selected control patients were seen and
underwent surgery for either one of the two diseases simul-
taneously treated in patients with coexisting diseases and
were expected to have at least similar or better results than
the study group patients. Therefore, the underlying hy-
pothesis of the study was that results of the simultaneous
approach to coexisting diseases were not significantly worse
than those of the treatment of the single-presenting disease.
Despite the incidence rate of the coexisting diseases being
rather high in this study, survival analysis was hampered by
the limited sample size (16 cases over 6 years) and the
slightly increased mortality rate observed in the study
group in the early follow-up period. Nevertheless, some
valuable conclusions can be drawn from the study results.
No perioperative mortality was observed. Systemic and
urologic complications were similar in patients undergoing
simultaneous surgical treatment of coexisting AAA and
TCCB and surgery for bladder cancer alone. Concomitant
TCCB and AAA treatment did not increase the risk of
vascular graft infection and other vascular complications.
Preoperative renal insufficiency may represent a particular
risk for increased short-term mortality in patients undergo-
ing the simultaneous treatment, and special attention
should be given to renal preoperative function evaluation
and perioperative treatment. Long-term survival of simul-
taneously treated patients is mainly dependent on cancer
progression.
This study shows that the simultaneous surgical ap-
proach to coexisting AAA and TCCB may represent a
suitable choice of treatment in specialized centers. When-
ever anatomic characteristics are suitable, endovascular
therapy of AAA in patients with coexisting TCCB is an
appealing alternative to simultaneous surgery.
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